Merck KGaA (MRK) Earnings Call Transcript & Summary
August 6, 2026
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and thank you for joining us for the Merck Investor and Analyst Conference Call covering the second quarter of 2026. <<operator_script>> At this point, I'll turn things over to Florian Schraeder, our Head of Investor Relations, and he will guide you through today's conference. Please go ahead, sir.
Florian Schraeder
executiveThanks so much, Heidi. Good afternoon, good morning, everyone, and welcome to the call covering our Q2 '26 results. We appreciate you being with us today. I'm Florian Schraeder, Head of Investor Relations at Merck. On today's Q2 call, Kai Beckmann, our Group CEO, will start by sharing an update on the first steps taken since we announced our new strategic direction in May. Kai will then give a brief overview of how the business performed and the key developments in the second quarter as part of his executive summary. Helene von Roeder, Group CFO, will walk you through the detailed financial overview. Before we get to the Q&A session, where Jean-Charles Wirth, CEO of Life Science; Danny Bar-Zohar, CEO of Healthcare; and Benjamin Hein, CEO of Electronics will join us, Kai will share our updated outlook and guidance with you. With that, I'm happy to hand things over to Kai to get us started.
Kai Beckmann
executiveThank you, Florian, and good afternoon, good morning, and thanks to all of you for joining us today. So before we turn to the numbers, allow me first to give you a sense of our strategic position and to highlight the milestones we've achieved in recent months since announcing our strategic direction in May. Every one of these milestones responds to the evolving expectations of our customers and patients in an increasingly complex world. Geopolitical tensions, shifting trade dynamics, active policy debate and accelerating AI-driven technology rates are all shaping the environment in which we operate. Against that backdrop, only a clear plan and disciplined execution will bring us closer to the sustainable profitable growth we are building for our company. Allow me to share a few early proof points. Let me start with the signing of a definitive agreement to acquire Bio-Techne Corporation on June 25. Subject to regulatory approval and closing, Bio-Techne's complementary portfolio of high-quality reagents, analytical instruments and diagnostic systems for precision medicine is expected to be immediately accretive to sales growth and margins. At the same time, we continue to invest in the capacity required to scale our manufacturing and R&D in electronics, delivering precise, reliable and scalable solutions across the semiconductor value chain.
Kai Beckmann
executiveBack in June, we opened a new site for metrology and inspection close to Grenoble, France. That EUR 20 million investment boosts our capacity for M&I tools in a major semiconductor hub. Strong momentum continues across our rare diseases portfolio, and our pipeline has moved forward as well. Both Xevinapant and GOMEKLI posted growth quarter-over-quarter and year-over-year. On top of that, pimicotinib recorded its first sales in China, and preparations for a U.S. launch are underway. The FDA awarded breakthrough therapy designation to enpatoran for treating lupus with active cutaneous manifestations. Also, the first patient has been dosed in a Phase III trial testing our anti-CEACAM5 antibody drug conjugate, Precem-TcT, for third-line treatment of metastatic colorectal cancer. So that's where I'll stop for today. Looking ahead, we'll keep sharing further proof points showing that our investments are focused where the strongest growth opportunities lie. Customers will find it easier to work with us thanks to more integrated solutions, and we'll share capabilities more effectively throughout the company. We'll also keep using partnerships and acquisitions wherever they speed up progress. With that, let me move to our operational and financial performance in the second quarter. So Q2 was a pretty robust quarter.
Kai Beckmann
executiveAfter a strong beginning to the year, we're carrying that growth momentum forward into the second quarter. Our organic sales growth sped up to 4.1%, with robust contributions coming from both Life Science and Electronics. Within Life Science, growth was spread broadly across every region. Once again, Process Solutions turned in strong growth, with sales rising 15% on an organic basis. And just to remind everyone, we anticipate the growth profile will normalize during the second half of the year. Advanced Solutions likewise posted solid growth, whereas Discovery Solutions saw only slight growth amid a market environment that remains muted. On the Healthcare side, as I mentioned, rare diseases kept making a meaningful contribution. To align more closely with how we operate, we've reorganized the remaining franchises. Cardiometabolic is now reported on a stand-alone basis, and Fertility & Endocrinology has been set up as a newly created franchise. Both were broadly stable during the quarter. Specialty Care, made up of neurology and oncology assets, drove the overall organic decline in Healthcare, largely reflecting the impact from MAVENCLAD in the U.S. as well as continued competition for BAVENCIO. Turning to Electronics, organic growth accelerated significantly, reaching 12% in Q2. Semiconductor Solutions delivered very strong organic growth of 17%, powered by continued momentum in advanced nodes. Optronics stayed broadly stable, while headwinds in consumer electronics end markets are expected to intensify further.
Kai Beckmann
executiveSo because of that, we hit our goal of producing profitable organic growth for the group, and we kept putting money into innovation at the same time. EBITDA pre margin rose versus a year earlier by 1.6 percentage points, reaching 29.4%. Given these strong results, we're lifting our guidance for the full year, and later in this call I'll walk you through the specifics. Turning to Page 6, where the group bridge is shown in greater detail: reported net sales were up 3.4% from a year ago in Q2. Organic sales growth came in at 4.1%, with Life Science and Electronics driving that. Currency had a negative effect of minus 1.1%, while portfolio effects added 0.4%. During Q1, organic growth of 2.9% was more than outweighed by outsized foreign exchange headwinds along with negative portfolio effects. In this quarter, the overall combination of organic growth, FX and portfolio effects showed clear improvement, which produced faster growth momentum. Organic EBITDA pre growth was a pleasing 9.3%, helped as well by favorable comps in Electronics in Q2 2025. I'll now pass it to Helene, who will share more details.
Helene von Roeder
executiveThanks so much, Kai, and a warm welcome from me as well. So with that, let's dive into the overview of key financials on Page 8. Net sales rose from EUR 5.255 billion in Q2 '25 to EUR 5.434 billion in Q2 '26. As already mentioned, solid organic growth and easing currency headwinds drove this, while portfolio effects in Healthcare and Electronics largely offset each other. EBITDA pre rose from EUR 1.46 billion to EUR 1.6 billion. The organic increase of 9.3% came primarily from Life Science and Electronics, while foreign exchange and portfolio effects were close to neutral, leading to reported growth of 9.4%. EPS pre rose by 6.9% to EUR 2.16. And this was achieved despite a visible increase in interest costs related to the financing of SpringWorks acquisition. However, for the full year, we slightly reduced our interest cost guidance, as you can see in the appendix. Operating cash flow rose moderately by 6.7% to EUR 605 million, which does not tell the full story. Temporary effects are partially offsetting structural improvement, and I will come back to this in a minute. Net financial debt rose to EUR 9.2 billion as of June 30, mainly due to the dividend payment.
Helene von Roeder
executiveMost of that working capital rise comes in Q1, with smaller bumps in Q2, and it's basically tied to foreign exchange effects. Now, one housekeeping point I'd like to raise already today is the possible impact from implementing IFRS 18. IFRS 18 takes effect as of January 2027. Right now, the EBITDA pre calculation is built on EBIT. Going forward, EBITDA pre will rest on the newly defined IFRS 18 operating profit or loss, to which we'll add depreciation and amortization along with adjustable items. Without diving into the details at this point, our simulations indicate that the gap between past and future EBITDA pre comes in under 2%. Some definitions of certain adjustments will change with the introduction of IFRS 18. We've put together a slide in the appendix of this deck that walks through those changes. We'll share further insights as we get nearer to implementing IFRS 18. With that, let's turn to the performance analysis of the three businesses. I'll begin with Life Sciences on Page 9. Life Science sales rose 8% organically in Q2. Process Solutions was the key driver once again.
Helene von Roeder
executiveLike we mentioned back in Q1, the business is getting a lift from solid underlying demand, helped by purchasing activity in APAC that's stronger for now and by new customer projects. We were already seeing that toward the close of Q1, and the temporary boost carried over into the start of Q2. But as we expected, it began to normalize as the quarter went on. Past that, we aren't seeing any unusual effects. We've had no significant delays in customer projects, and we don't see reliance on any particular product groups. Our performance is still broad-based. That said, the assumption we shared with you on our May call — namely that the second half normalizes in the second half of '26 — does remain valid. As expected, the Process Solutions order book normalized in Q2. Advanced Solutions and Discovery Solutions are on track. Advanced Solutions grew 4% organically, with the research spending environment gradually improving. And Discovery Solutions grew 2% organically despite a muted market environment, including continued softness in China. EBITDA pre rose to EUR 700 million, with the margin expanding by 50 basis points to 29%. At the same time, we keep investing in R&D as a key driver of our future growth and differentiation.
Helene von Roeder
executiveAmong these investments, for instance, is the introduction of the Viresolve Pro-S solution — a virus filtration product built to be more sustainable while boosting throughput for complex, high-concentration monoclonal antibodies. We also brought out our first bio-based high-performance liquid chromatography solvents, or HPLC solvents, which on average release roughly 26% less CO2 equivalent with no sacrifice in performance. Stepping back, two further topics deserve mention. The first is tariff refunds. The impact of tariff refunds passed to customers proved immaterial during Q2. Across the full year, those effects are captured in the updated guidance that Kai will walk through in detail shortly. The second, naturally, is our plan to acquire Bio-Techne. No news is good news. Everything remains on track. On the accounting treatment for the pending Bio-Techne acquisition, let me remind you that material effects — such as recognition of transaction costs — will only appear after closing, which we expect by the end of this year or in early '27. Once closing occurs, we would anticipate immediate EBITDA pre margin accretion. We estimate run rate cost synergies of approximately EUR 140 million by year 3 following closing — the same year in which we also expect to see EPS pre accretion at group level.
Helene von Roeder
executiveLet's turn now to Healthcare, which you'll find on Page 10. Sales for the reported segment rose 2.4%, reaching EUR 2.2 billion. In organic terms, sales were down 3.4%, though positive portfolio effects from our rare disease portfolio at 5.4% more than made up for that decline. Within rare diseases, OGSIVEO and GOMEKLI together posted EUR 207 million in sales during H1, which is fully in line with our guidance. We also recorded initial sales of pimicotinib after the private market launch in China. Cardiometabolic sales rose 1% organically, amid continuing constraints in the Middle East and a partial reversal of the positive phasing in China that we flagged to you in Q1. Fertility & Endocrinology sales were roughly flat. Pricing for GONAL-f in the U.S. began to normalize, Pergoveris kept delivering double-digit growth, and Saizen came in slightly up against tough comps. Specialty Care fell 6% organically, largely reflecting MAVENCLAD's loss of market exclusivity in the U.S. and the competitive environment for BAVENCIO. Of note, Erbitux sales grew 5% organically. We have also seen progress in the late phases of our pipeline. The first patient has been dosed in our Phase III study of Precem-TcT, our first-in-class anti-CEACAM5 ADC in third-line metastatic colorectal cancer. In addition, the FDA has granted breakthrough therapy designation to enpatoran for treating lupus with active cutaneous manifestations.
Helene von Roeder
executiveAlso, we recently — sorry, we also recently got file acceptance from the FDA for Pergoveris. That said, uncertainty is still there. Healthcare EBITDA pre came in at EUR 747 million, with a margin that remains strong at 34.7%. A favorable product mix and disciplined cost management support this, partly offsetting higher R&D investments, which reflect the ramp-up of our Phase III pipeline projects as well as launch investments in rare diseases. Now let's turn to Electronics. Electronics had a strong quarter, with organic sales growth accelerating to 11.7%. Reported sales were EUR 871 million, reflecting the portfolio effect from the divestment of Surface Solutions. Semi Solutions grew 17% organically, fueled by continued demand in semi materials, driven by advanced nodes in both logic and memory. Overall, all parts of the portfolio supported growth. Delivery Systems & Services also had a better quarter thanks to the finalization of a large project and against a low base. So I would caution against extrapolating this trend. Optronics remained roughly stable. However, the business still faces headwinds from softer demand for consumer electronics, influenced by high memory prices. This could result in a year-over-year decline in net sales in the second half.
Helene von Roeder
executiveEBITDA pre rose to EUR 244 million, and the margin widened to 28%. That's a sequential gain of roughly 200 basis points compared with the underlying EBITDA pre margin in Q1. As a reminder, one-offs held down the EBITDA pre margin in Q2 '25, which came in at 15.1%. Even after adjusting for those effects, the underlying margin increase year over year would still have been significant. Now, briefly on key balance sheet developments. Total assets came to EUR 52.7 billion at the end of June. Cash and cash equivalents declined, largely because of euro-denominated bond repayments. Receivables rose on the back of continued strong sales performance, and inventories grew mainly in Life Science and Healthcare to support future growth. It's worth noting that the main uplift in receivables and inventories came in Q1. The additional increase was essentially driven by FX effects in Q2. Intangible assets rose primarily because of foreign exchange effects. On the liability side, financial debt was up versus year-end '25, since the euro-denominated bond repayment was offset by a rise in financial liabilities to related parties and by the U.S. dollar bond increase due to foreign exchange effects. The equity ratio edged up slightly to 57%. And I'd like to wrap up with a few comments on cash flow.
Helene von Roeder
executiveCash flow from operations came in at EUR 605 million for Q2, compared with EUR 567 million a year earlier, even though profit after tax declined. That profit figure was pressured by reorganization provisions, rising R&D costs, and greater depreciation and amortization, largely tied to the SpringWorks acquisition. Favorable underlying gains appeared across most lines of the cash flow statement, and net working capital optimization deserves particular mention. Those benefits, however, were countered by temporary shifts in the tax balance and bond interest that was paid. Recent months have shown clear improvement in underlying cash generation, and this will stay a strong priority ahead as we pursue rapid deleveraging once the planned Bio-Techne acquisition closes. Investing cash flow rose, reflecting short-term investments and payments tied to the purchase of the JSR chromatography business. Financing cash flow captured repayment of the euro-denominated bonds. With that, I'll hand it back to Kai.
Kai Beckmann
executiveThanks very much, Helene. Now I'd like to wrap things up by walking you through the guidance we've raised for 2026, which you'll find on Slides 15 and 16. We now anticipate organic growth of 1% to 3% in group net sales, versus 0% to 3% before. Relative to the prior guidance, we're seeing foreign exchange headwinds ease. The FX impact is now projected at minus 2% to 0%, compared with minus 3% to minus 1% earlier. As a result, group net sales should come in at roughly EUR 21 billion to EUR 21.8 billion. This range's midpoint matches the top end of our earlier net sales guidance of EUR 20.4 billion to EUR 21.4 billion. On EBITDA pre, our expectation now stands at EUR 5.9 billion to EUR 6.3 billion, up from EUR 5.7 billion to EUR 6.1 billion previously. That mirrors an organic development of 0% to 3%, against minus 2% to plus 2% before. EPS pre should land within EUR 7.90 to EUR 8.60, which is a 5% increase over the earlier range of EUR 7.50 to EUR 8.20. At the business sector level, you can see how all these figures fit together.
Kai Beckmann
executiveOn the Life Science side, we're lifting the bottom end of our projected organic net sales growth range — it moves from 4% up to 5% now. That updated 5% to 7% organic sales growth range also bakes in a possible headwind of roughly EUR 40 million tied to tariff refunds for customers. For EBITDA pre organic growth in Life Science, the expectation now sits at 5% to 8%, versus 4% to 8% before. The roughly EUR 2.6 billion to EUR 2.8 billion range stays as it was. Turning to Healthcare, organic net sales development is now projected at minus 4% to minus 2%, where May had it at minus 6% to minus 3%. That shift comes from our assumptions around MAVENCLAD U.S., where we now assume 0 sales as of August, along with somewhat better performance across the rest of the business. Our assumptions still leave out the possible 2026 U.S. launch of Pergoveris. Also, effective July 1, OGSIVEO and GOMEKLI will be counted as organic sales. So the associated portfolio effect is confined to the first half of the year and comes to plus 2.4%, or EUR 207 million in absolute terms. EBITDA pre for Healthcare is now anticipated at around EUR 2.8 billion to EUR 3 billion, up from EUR 2.6 billion to EUR 2.8 billion previously.
Kai Beckmann
executiveWhen it comes to Electronics, we're lifting our organic net sales growth guidance to 6% to 9%, up from the earlier 3% to 7%, and the portfolio effect stemming from the Surface Solutions divestment comes to minus EUR 245 million. EBITDA pre for Electronics is now projected at roughly EUR 1 billion, versus the prior range of approximately EUR 0.9 billion to EUR 1 billion. The corresponding organic growth range shifts from 21% to 27% to 25% to 29%, which mirrors the recovery and operating leverage in Semi Solutions. So with that, let me wrap up with a quick summary before we open the lines for Q&A. We posted a robust second quarter, with organic sales growth accelerating and organic EBITDA pre growth that was even stronger. The first half of the year bears out the resilience of our broad portfolio and the relevance of the strategic priorities we laid out earlier this year. We're encouraged by the continued momentum in Life Science and Electronics, and we stay disciplined in Healthcare as we put investment into our launches and pipeline. Our raised full year guidance reflects these positive developments. And we'll keep our focus on executing our strategic agenda, including a potential start of the Bio-Techne integration following a successful closing potentially at the end of this year or early next year.
Kai Beckmann
executiveWe'll keep cost discipline as a priority, and at the same time we'll keep putting money into innovation so we can sustain profitable growth down the road. So with that, I'll hand it back to Heidi now so she can open the lines for questions.
Operator
operatorOur opening question today comes from Peter Verdult, who is with BNP Paribas.
Peter Verdult
analystI'll start with two questions for Kai or Helene. Shares have performed strongly in 2026, yet the main discussion among investors is shifting rapidly toward 2027 and whether Merck can deliver organic growth, considering the tailwinds from MAVENCLAD and Life Science customer stocking that benefited you in 2026. Of course, I understand you won't provide formal guidance on a Q2 call, but I'd like to probe a bit and hear how confident you currently feel regarding organic growth in 2027. Second, a somewhat thornier one for Danny: it's encouraging that Pergoveris has been filed. Certain uncertainties were highlighted during the prepared remarks. Could you verify that those remarks pertain to the label ultimately granted rather than Pergoveris's approvability? And assuming that's right, could you remind us what the most favorable outcome would be regarding the label — the FDA label — if the product is approved?
Kai Beckmann
executiveThanks, Peter, for that question about 2027. We've raised our guidance on two occasions during this year. Life Science and Electronics are delivering fairly strong growth, and Healthcare is holding up reasonably well despite the generic competition that we're encountering. When we look ahead to 2027, the fundamentals and underlying trends remain very much intact for Life Science and Electronics, while Healthcare is concentrating on carrying out the strategic agenda next year. Essentially, 2027 ought to be well aligned with the projections we shared at last year's CMD. As an initial highlight, it will be very much in line with those projections from last year's CMD. Of course, the comparables will be tough for MAVENCLAD, without question. And Process Solutions will face a high comparison base during the first half of 2027, since we're comparing against a very strong first half in 2026. Turning to the proposed transaction to acquire Bio-Techne: if it closes in line with our plans, it would contribute close to 5% to group sales growth and roughly 10% to Life Science alone. In addition, the transaction would be immediately accretive to group EBITDA pre margin, and we are committed to EPS pre accretion in year 3 post closing. That should give you some color on how we view 2027 from today's perspective.
Kai Beckmann
executiveAnd as you correctly noted, at this point in the year we aren't giving any 2027 guidance, of course, but just a bit of color on what you asked. And I'll pass it over to Danny for the second question.
Danny Bar-Zohar
executiveThanks, Kai. Hi, Peter. So yes, late last week the FDA notified us that it has accepted the full BLA submission. In itself, that is good news, yes. It's a good milestone. Pergoveris is a great product. As Helene said, though, uncertainty remains regarding the potential approval, and I'll give you a bit more color on that. First of all, just to frame it, Pergoveris is the only recombinant FSH LH combination on the market. And I would say it's an important innovation for patients who need that. The product is approved in 116 countries around the globe, including China since February this year. It's been growing and taking share in every market where it's available, underpinning the value it brings to women struggling to have a baby. As a matter of fact, over 6 million babies have been born worldwide with our fertility medicines. In 2026 only, year-to-date, Pergoveris generated sales of over EUR 300 million, 5 years CAGR of over 20%. Now of course, we are keen to bring Pergoveris also to the U.S., one of the largest and most innovative pharma markets. We were, I would say, delighted to have received the CNPV as part of our agreement with the White House at the end of last year.
Danny Bar-Zohar
executiveBut as we mentioned earlier, the procedure itself is fairly new, and the submission relies heavily on legacy data, much of it generated outside the United States. So you should also bear in mind that over the past years, we've already held extensive discussions with the FDA regulator and were unable to reach agreement on a path forward. Therefore, we believe there's significant uncertainty regarding Helene's point about whether the package is now sufficient for the FDA to grant approval. You also asked what a best-case label might look like. Here, I'd readily point you to the EU label or the Canadian label, so you can get a sense of it. That's where we stand right now with Pergoveris.
Operator
operatorMatthew Weston from UBS is up next with a question.
Matthew Weston
analystLet me ask two things, if I may. First, regarding Process Solutions, and this relates to how we normalize across the quarter. I believe I follow, but I'd like you to lay it out clearly. Is the point that the additional demand has come to a halt, yet that extra inventory is still sitting with the customer, and so at some future point we ought to expect that inventory to draw down? And I believe you've previously mentioned that no single customer accounts for more than 5% of PS sales, but my assumption is we can't make a comparable statement about the inventory — it will be more concentrated. Second, on atacicept royalties, there's been considerable discussion about their leverage to Merck in the market. I know you've addressed this before. Could you remind us what portion of the royalty you get and what portion must be passed on?
Jean Wirth
executiveJean-Charles here. I hope you're doing well. Let me try to make the situation clearer. I'll begin with Q2. In Q2, within Process Solutions, organic growth came in at 15%. I'd like to give you some context behind that. There are five main drivers. First, market demand is still healthy. Second, we keep gaining from our new go-to-market model. A few months back, I noted that we're lifting our sales level, and that has a favorable effect on our overall performance. The third element ties to what I said in May, when I noted that we had seen, particularly in March, unusual buyer patterns from a few — very few Asian customers, connected to the ongoing geopolitical situation — let's call it the Middle East conflict. Driver four was exceptional growth in China, largely because some customers ordered equipment in order to build new plant. And the final element relates to the fact that we're getting some boost in order intake and sales from non-repeat orders, which tie to our integrated workflow solution offering. To answer your question: of the five drivers, the last three are the ones lifting our performance in Q2.
Jean Wirth
executiveRegarding what you asked about inventory destocking, we don't expect any effect from it in 2026. However, in your model you should assume that any inventory destocking effect, should one occur, could happen in 2027.
Danny Bar-Zohar
executiveOn atacicept, yes, the drug got approved for IgA nephropathy a few weeks back. And to your question, Matthew, it's fair to assume there's still a meaningful obligation owed from Merck to BMS when it comes to potential milestones and royalties. And since we're expecting a launch here, in just about every scenario, the net royalty rate — the net royalty rate upside — would stay with us in the single-digit percentage range.
Matthew Weston
analystMind if I press you on that? I understand the original out-licensing deal included roughly EUR 600 million in milestones. Would it be reasonable to expect that Merck would also receive milestones as the launch progresses and certain commercial revenue thresholds are reached?
Danny Bar-Zohar
executiveYes, that’s correct.
Operator
operatorWe’ll move on to the next question now. This one is from Sachin Jain at Bank of America.
Sachin Jain
analystI have a few questions of my own. First, to follow up on the process topic: can you verify that for the full year, the process is still at the upper end of the 8% to 12% range you mentioned on the previous call? Or does the first-half strength push it a bit above that, based on what the second half would imply? My second question is on Semi — specifically the durability of the mid-teens for materials and what is baked into the guidance. Then I just want to clarify the '27 remark, Kai, and I apologize for this. It sounded to me as though Bio-Techne was the primary offset to the harder comps in the base? Or are you affirming mid-single-digit organic growth, which is what you stated at the '25 CMD? Sorry for needing that clarification.
Kai Beckmann
executiveLet me address the 2027 question first, Sachin, to make things clear. So the remark about the commitment from the CMD is organic, of course. And then the second remark concerning Bio-Techne is, of course, the reported effect. Those are just the two elements I wanted to highlight. But what matters is that the CMD's comment is the organic part.
Jean Wirth
executiveSachin, this is Jean-Charles. I'll take the first question about Process Solutions. To begin with, I'd like to use this chance to discuss our book-to-bill ratio. When you examine that ratio for the year to date through June — so for H1 — it sits above 1. As for what we're assuming now, we expect Process Solutions growth to normalize in the second half, though our book-to-bill ratio ought to stay above 1. Against that backdrop, we see solid underpinning for our growth. And regarding the 8% to 12% range we provided, our thinking is that we'll land in the upper end of the full-year guidance.
Danny Bar-Zohar
executiveDanny here — thanks so much, Sachin, for that question about Semi. Let me give a quick recap: Semi Solutions posted 17% growth in Q2, and this business is what's driving the wider electronics business, both this year and over the midterm. As a reminder, Semi Solutions is made up of semiconductor materials, which represent roughly 65% of overall Electronics sales, plus the Delivery Systems & Services business — DS&S for short — which makes up under 15% of total Electronics sales. So on semiconductor materials, to get to your question, sales rose by a low double-digit percentage organically. Why is that? Largely because of AI-related applications in advanced nodes, on both logic and memory. It's also encouraging that every part of the portfolio is contributing to that growth. And as you'll recall, across the past 10 quarters, this business has averaged low teens growth. On top of that, in Q2 we also had DS&S adding to Semi Solutions growth. That's not likely to repeat. Our expectations for DS&S improved only moderately. For the remaining quarters of this year, we see a broadly stable outlook. And stepping back for a moment, by and large, the leading-edge customers in particular — the ones behind the AI-driven growth — are still capacity constrained, both this year into the second half and well into 2027.
Jean Wirth
executiveSachin, this is Jean-Charles, and just so there's no confusion: the 8% to 12% organic growth figure I brought up for the full year referred to the Process Solutions portfolio. And to give you a bit of color, I can confirm we continue to have active engagement with customers right now. We keep an eye on our book-to-bill ratio, our order intake, and our order book. What I was trying to convey is that we have a lot of confidence about 2026 when it comes to Process Solutions.
Operator
operatorWe’ll move on to the next question. The question is from James Quigley at Goldman Sachs.
James Quigley
analystTwo questions, please, and I believe both are for JC. The first one, unsurprisingly, is a follow-up on PS stocking. You attached a pretty sizable condition to how much destocking could affect 2027. So what kind of visibility do you actually have into customers' inventory levels? Could there be a scenario in which those higher inventory levels turn out to be the new normal for those customers, or where they reverse or destock at a fairly slow pace, making the 2027 headwind quite minimal? Second, over roughly the last 18 months we've heard plenty about CapEx investments from your pharma customers in the U.S. Are you beginning to see any progress on the significant capacity expansions that have been planned? Given a portfolio focused on consumables, presumably it takes some time before that flows through to Merck. But have you started any discussions, pitches, RFPs, or anything along those lines with customers as they begin assessing their CapEx plans? And how are you making sure Merck secures its fair share of that capacity once it comes online?
Jean Wirth
executiveOn your first question about PS stocking, I'd say that right now — bear in mind it's July — our visibility into 2027 is limited. Having said that, what I can share is that the quality of our orders has returned to where it stood before COVID, in terms of order lead time. So we're quite comfortable saying the inventory impact, if any, would show up only in 2027, not in 2026. As for your second question, on CapEx from large pharma customers, the answer is yes, we are in ongoing discussions with the large pharma customer. In fact, I visited one a few weeks ago, and I have one important meeting scheduled in September with one of our largest customers. Let me take this chance to go back to Matthew's question and note that our largest customer accounts for under 1% to 2% of total revenue in any business unit — whether you call it Process Solutions, Advanced Solutions or Discovery. On CapEx, yes, we have exchanges. Yes, we are meeting, but it's too early to move forward with a clear view. Discussions are ongoing. And maybe my last comment: bear in mind that the bulk of our portfolio is driven by consumables, not equipment.
Jean Wirth
executiveSo I do think there’s going to be some benefit at some point, but near term, no.
Operator
operatorLet's go to our next question, and it's from Richard Vosser at JPMorgan.
Richard Vosser
analystTwo questions, if I may. Starting with the CEACAM5 ADC: some intriguing data emerged at ASCO in a different tumor type, pancreatic. So I'm just wondering about possible development across additional indications and additional tumors past third-line colorectal cancer. Are you still seeking a partner so you can step up investment in this product? How are you approaching that going forward? Second question — apologies for dwelling on Process Solutions. For the second half, it sounds like you're guiding to an underlying growth rate of roughly 10% to 12%, though we ought to subtract tariff returns of about EUR 40 million from it. Are there any other headwinds we should factor in for the second half? And then one last small point on Process Solutions. That new market model you mentioned — should we view it as actually letting you compete more effectively, perhaps even, dare I say, take some share from competitors here? Is that something we should expect, or is it a bit early for that?
Danny Bar-Zohar
executiveRichard, Danny here — I'll field the opening question about Precem-TcT, the CEACAM5 asset. Yes, this first-in-class ADC makes us quite proud, and the data we presented at ASCO, initially in colorectal cancer, remains highly encouraging. So you're correct: during last year's CMD, we indicated we'd explore the possibility of partnering this ADC. And in fact, over the last couple of months, we've held some very productive conversations with multiple parties who expressed interest. At that same CMD, I also stated — and David shares this view — that we'd be extremely disciplined about capital allocation and would focus on single assets carrying a lot of correlated risk. Ultimately, we reached the conclusion that at this stage we won't move forward with partnering Precem-TcT. We'll keep developing this compound in third-line metastatic colorectal cancer. That's a massive global Phase III trial. It represents a substantial opportunity for us. and we're able to pursue it independently without sacrificing our strategic priority of, as I mentioned, lowering high capital intensity tied to correlated risk. Regarding earlier lines of treatment, along with the pancreatic cancer data you brought up, we will — above all, we're dedicated to capturing the value of this compound, but we'll do so in a stage-gated and, I'd say, highly disciplined way.
Danny Bar-Zohar
executiveWe’ll therefore have to watch how the colorectal cancer trial advances, and after that we’ll make further choices regarding combinations and other tumor types. The pancreatic cancer data are in fact favorable. It indicates that the drug is active—we remain cautious—and we’ll provide updates as data become available.
Jean Wirth
executiveRichard here, Jean-Charles speaking. So, regarding your first question about Process Solutions for H2 — if you look at H1, we're off to a very, very good start right now. And I said that for the full year in Process Solutions, we expect to land within the 8% to 12% range. And if you peel the onion and go one level deeper, in the high range of this guidance. So if you do the math, you know exactly what our organic growth for H2 should be. And as of now, we don't see any headwinds or anticipate any headwinds. Again, I'd like to talk about normalization for H2. Concerning the process market model, the go-to-market, overall, we are making good progress. We are completely done with the redesign. Everything is set — sales incentive, territory mapping — and the feedback from our customer is extremely positive. I'm very pleased with where we stand today. Too early to say that we are more competitive or that we are gaining market share. But you should assume that I have a big smile and I'm very, very happy where we stand.
Operator
operatorCharles Pitman from Barclays has the next question.
Charles Pitman
analystTwo from me, if I may. First one’s for Danny, on MAVENCLAD and the U.S. strategy and outlook. Based on the IQVIA data, broader U.S. prescription volumes for cladribine have actually been falling even though you’d normally expect generic competition to push volumes higher. So I wanted to ask whether you can confirm this reflects a deliberate pullback in Merck’s marketing efforts and more share going to competitors, or whether it just shows a weak capture rate for IQVIA. And could you give us a bit more detail on how you’re defending on price or volume right now, and how you expect erosion to play out starting August ’27, when the European patent expires? Then my second question is on Electronic margins in DS&S. Obviously DS&S has been somewhat lumpy. I’m wondering whether you can give us more insight into how near we are to a more normalized growth rate, given you’re saying it will moderate in the second half of this year. I’m also trying to understand what impact the DS&S project had on margins in 2Q and how we should think about margins into 2H, given 1H came in around 31% versus the full-year implied 29% to 30%, which implies that’s greatly derisked.
Danny Bar-Zohar
executiveCharles, this is Danny. I'll begin with the MAVENCLAD question. Regarding MAVENCLAD in the U.S., Q2 sales were, I'd say, nearly level with Q1, though the trend began softening near the end of the quarter, just as an FYI. In fact, MAVENCLAD is experiencing slower generic erosion compared with prior analogs, owing to slower generic registration and limited penetration. Two generics have been approved. That said, additional generics are queued for approval in due course, with two of them potentially reaching the market, per our assumptions, still in this quarter — the third quarter. So with that, if we're discussing our capacity to guide, we'll stick with this guidance methodology. Now, just as an FYI, regarding MAVENCLAD outside the U.S., growth has been very strong. Europe, for instance, rose 32% in Q2, with very strong commercial execution and significant uptake of year 1 patients. So now, if we're discussing the full year 2026 outside the U.S., we anticipate double-digit growth for MAVENCLAD. Now, as you mentioned, the loss of — or the expiry of the regulatory exclusivity in Europe is expected in August 2027.
Danny Bar-Zohar
executiveSPCs do exist, yes. That said, my strong recommendation for modeling purposes is that you use August 2027.
Benjamin Hein
executiveBen here, Charles — thanks a lot for the questions. I'll begin with DS&S. If you look at Q2, DS&S in fact did contribute to growth in Semiconductor Solutions, and the reason specifically was that a large project got finalized during that quarter. As you're aware, that follows a stretch where performance was relatively weak, and after that, DS&S growth normalized toward the end of last year. And as we reported last time, in Q1 it was flat quarter-over-quarter. For DS&S, our expectation is only moderate improvement. So compared with the second half of last year, we see a broadly stable outlook for the second half of this year. Just as a reminder, DS&S has three components. One is the large projects business, which we manage opportunistically, so don't put it in your base. The second one is equipment for gas delivery, but also chemical delivery. And the third element is the recurring service model. On the margin question itself, we've done a good job in Q2 on managing our margin. We have committed to you that we will work on margin expansion quarter-over-quarter, year-over-year. We've delivered on that commitment. We saw around 200 basis points increase quarter-over-quarter from Q1, so it's a solid expansion.
Benjamin Hein
executiveLooking at it, our EBITDA pre margin in Q2 stands at 28%, a significant increase from 15.1% in Q2 of last year. I'd note this was a clean quarter, so you shouldn't factor in any meaningful onetime effects for Q2 this year. As you'll recall, though, Q2 last year was depressed mainly because of two onetime effects that we flagged. On the reported EBITDA pre margin, there may be support, as Helene mentioned, from FX backwinds of roughly 1%, and also from the portfolio effect — around minus 6% — coming from the divestment of Surface Solutions. So all in all, EBITDA pre rose 87.5% organically versus the prior year. We're seeing margins expand. We keep working on structural margin progression. What's behind that is, of course, the portfolio effect from Surface Solutions, worth roughly 100 basis points annualized. Second, operational leverage from higher volumes. Third, we're actively managing our cost position, as highlighted earlier. And then last but definitely not least, we also see a positive mix effect thanks to strong demand driven by AI applications in the market, especially data center build-outs.
Operator
operatorOur following question is from Falko Friedrichs at Deutsche Bank.
Falko Friedrichs
analystI've got two questions, if I may. First, regarding the Discovery Solutions business inside Life Science: could you give us a little more detail on the end market trends you saw during the second quarter outside of China, and particularly in the U.S.? Then my second question is about the semi materials business once more. Are you beginning to see a positive inflection in AI-related demand for your products?
Jean Wirth
executiveFalko here, and Jean-Charles speaking. Let me begin with your question about Life Science in relation to Discovery Solutions. First off, I want to point out that we're now heading into four consecutive quarters. Going back to what I said about go-to-market, we are at this point fully leveraging our multichannel approach. By multichannel approach, what I mean is that we sell directly. We use our e-commerce platform. We also sell through dealers, and we're seeing the benefit of having better focus on this portfolio. As for customer segments, every segment is improving, with the exception of academia, which stayed fairly soft, mainly in two countries, U.S.A. and China. That said, speaking of China, I mentioned a few weeks ago as well that we have just promoted a new Head of China. That individual reports to me. He sits on the executive team, and right now we are in the process of assessing what we could do strategically in China to make sure we are going to win in this market.
Benjamin Hein
executiveBen, it's Falko — let me handle the AI-related question. As we mentioned earlier, we're already benefiting today from growth driven by AI. Looking at the end market, data center build-outs overall remain strong. At the same time, consumer electronics is still somewhat muted. So the growth we're seeing is mainly coming from the AI-driven segment. Breaking that down, it involves both memory and advanced logic processing. That isn't a new development, but it's certainly a continuing driver. We've also updated our guidance, as Kai mentioned earlier today, to 6% to 9% sales growth for the year to reflect that demand growth. But again, I want to remind everyone to keep in mind our customers' capacity constraints, particularly in the AI segment, which are already occurring today and which we expect will extend well into next year as well as the industry debottlenecks.
Operator
operatorOur next question comes from Rajesh Kumar with HSBC.
Rajesh Kumar
analystRegarding Process Solutions growth in the first half, and those effects you mentioned, could you help us grasp how that may have affected or weighed on operating margins for the Life Sciences division? In other words, was the incremental cost of delivery notably above or below the usual level, along with the incremental drop-through margin, so that when we model our first half for '27, we anchor it on the right sort of run rate assumptions for drop-through margin? That is the first question. The second question concerns book-to-bill. I realize you have historically monitored how long order books last. In terms of numbers, that may be somewhat more subjective than objective. Still, when you look at your book-to-bill, are any meaningful duration shifts showing up in the order book — that is, are order lead times becoming significantly longer or shorter relative to the prior quarter or to long-term averages? Any insight on that would be greatly appreciated.
Jean Wirth
executiveKumar, I’ll do my best to respond. The connection was poor, so I’m not certain I fully caught your first question. As I understand it, though, it concerns how our profit margin is evolving. As you can imagine, we’re moving toward a quality-growth P&L, where the goal is for the bottom line to increase more quickly than the top line. Still, you should remember that we continue to face some absorption, or additional absorption, tied to start-up costs from our region-for-region initiatives, under which we have just opened new manufacturing sites or are in the process of opening them. To give just a few examples, last year we opened Blarney in Cork for Process Solutions. You should assume that we are now in the ramp-up phase, which means we have more cost than last year. And soon, in October, we will open a new manufacturing site in Asia, in South Korea, Daejeon, again for bioprocessing, and we are in the ramp-up phase right now as we speak. What I mean is that we are adding headcount without yet doing production. So that is extra cost for us. In addition, given the current performance of Life Science and Process Solutions, we are also deliberately increasing R&D investments.
Jean Wirth
executiveEarlier in the call, Helene brought up the launch of two new products, Viresolve and HPLC green solvent for Discovery. I could also mention CLX 8 for lab water. So what we're trying to do, given how things are performing right now, is speed up our innovation engine to ensure we get better at how we supply customers, at delivering a complete solution across their workflow, and so on. That covers your first question. As for the book-to-bill structure, I said previously that we rebuilt it back to 2019, before COVID. We refer to it as the Rainbow report. What I can share is that approximately 75% to 80% of our orders carry a lead time of 1 to 6 months, and that's precisely where we are at the end of June 2026.
Operator
operatorSimon Baker from Rothschild & Co Redburn has the next question.
Simon Baker
analystTwo questions, if I could, please. First, a wider one about M&A and business development after the Bio-Techne deal. I'm just wondering whether you could remind us of your capacity focus and your appetite for transactions following the Bio-Techne deal. Then, turning to Semiconductor Solutions. Kai, you brought up metrology in the — in your opening comments, and another company specifically called out growth from AI-related metrology. I just wanted to see whether you're seeing any effects from that. And then, more broadly, I wonder if you could update us on the outlook for memory capacity. We've seen some early signs that maybe capacity, from a very constrained position, is starting to expand, but you've probably got better oversight than anyone else really across that. So any update there would be really helpful.
Kai Beckmann
executiveSimon, I’ll address the M&A question. Naturally, Bio-Techne is what we’re working on diligently at present, and it demands our full attention as we prepare in the ways that are already possible for us and permissible for us, while also moving ahead with executing that transaction. That is our foremost priority. Then, as I noted in the strategy update, we have a very strong intention to replenish the early phase pipeline in Healthcare, and that is an important strategy. More broadly, we remain committed to strengthening our growth drivers, Electronics and Life Science overall. That is the work we are doing. During the financing of the current deal, we shared details with you. I think you can work out what might lie beyond that. But above all, we must be capable of carrying out these deals diligently. Integration matters greatly. So that gives you a picture of what we want to do and what we need to do, though of course we are constrained by what we can do in the end. Still, our priorities are set out in a very clear and straightforward plan. I’ll now hand over to Ben for metrology inspection, and he will focus on that.
Benjamin Hein
executiveThanks a lot, Kai. And thanks, Simon, for raising that. Let me give a quick recap on metrology and inspection. We brought that capability in through an acquisition, and metrology tools are used to measure critical parameters in chip manufacturing — things like depth, step heights and thickness — and they really make real-time adjustments possible, which improves process control. That matters a great deal, particularly in advanced semiconductor manufacturing, where the requirements around quality and purity keep getting tighter and tighter, especially as we move toward advanced packaging. Inspection tools, by contrast, catch a broad range of defect types, which also ensures the highest quality standards. So taken together, these technologies genuinely boost manufacturing yields, lower production costs and shorten time to market for the next generation of semiconductor innovation with our customers. It's a fairly small business for us. Integration is going extremely well. As Kai and Helene said earlier today, we've just opened a new facility so we can support our customers in terms of capacity, but also in terms of capability. On memory, the reality today is that memory chips are in shortage. Prices for advanced memory chips are very high. We expect this trend, or this situation, to continue at least until the second half of 2027.
Benjamin Hein
executiveWe’re putting in a lot of effort around the clock alongside our customers to debottleneck that capacity, but this isn’t something that will be resolved tomorrow.
Operator
operatorWe’ll move on to the next question now. That question is from Peter Spengler at DZ Bank.
Peter Spengler
analystStarting with Electronics: you posted 17% organic growth in Semiconductor Solutions, yet the Electronics division overall came in at only 12%. How do you account for that 5% gap? Then my second question concerns what's happening in bioprocessing. One of the big American competitors reported low single-digit growth in bioprocessing for Q2, and they attributed it to various factors. Is their weaker showing giving you a lift? Or are you running into the same shipment delays on the customer side?
Benjamin Hein
executiveThanks so much. I’ll begin with the Electronics question. To recap the different businesses: Semiconductor Solutions was up 17%. Overall, as you correctly noted, electronics sales growth in Q2 is about 12%. The explanation for that gap is that Optronics is basically flat this quarter.
Jean Wirth
executiveOn your question about the bioprocessing market — look, in connection with the go-to-market reorganization, we're putting the customer back at the center of what we do. So the number of interactions we have with customers has gone up. And while I won't comment on the competition, what I can say is that for Merck Life Science and bioprocessing as such, it's business as usual. We aren't seeing any variance or any trend that's abnormal.
Florian Schraeder
executiveHeidi, we’d have room for one final question, please.
Operator
operatorAnd the last question is from Oliver Metzger at ODDO BHF.
Oliver Metzger
analystThe first one is for JC. Regarding Process Solutions, you pointed out the robust purchasing trend in APAC. You also mentioned certain stocking impacts stemming from the Middle East conflict, but is there additionally some improving underlying demand, say? The second question is for Ben on DS&S in H2 of last year, when you reported some project shifts. So would you characterize the earlier-than-expected return to growth in Q2 as resulting from some of those projects coming back? Or do you still view them as being in your pipeline, with just their timing unknown? And the last one quickly — for Danny on fertility. So it was stable development. And we saw, owing to GONAL-f, some volatility across the last quarters. But could you share further insights into what is currently holding the business back?
Jean Wirth
executiveI'll begin with Process Solutions, and this is JC here. Our view remains that bioprocess is a highly appealing market, expanding at 9% to 10%. We also feel we're doing very well at this point, and have been for two quarters. Let me restate the key trends I mentioned: demand in the market is strong and healthy. We're seeing good gains from our go-to-market model, through which we raise our service level and place the customer back at the center of everything we do. Then, as I noted, we're observing a special buying pattern among a few Asian customers, exceptional growth in China, and lastly, some one-time uplift from an order we booked aimed at enhancing our customers' full workflow.
Benjamin Hein
executiveOliver, this is Ben. I’ll take the DS&S question. In Q2 2026, the biggest factor behind DS&S sales performance is the completion of one major large project that was already in our pipeline. So it was already being executed. And for H2 this year, we expect roughly flat results versus H2 last year.
Danny Bar-Zohar
executiveOliver, this is Danny. On the topic of Fertility, as you'll recall, under the new structure we're combining Fertility & Endocrinology with Saizen, though I'll do my best to give you the colors separately. So for Fertility & Endocrinology, momentum picked up, as Helene mentioned, going sequentially from minus 5% in Q1 to minus 1% in Q2. The main driver there, I'd say, was the fading headwinds on GONAL-f tied to U.S. pricing. And as we've shared with you previously, we cut the price in Q2 of last year, and that has now begun to annualize. We're also seeing a modest rebalancing in the channel mix in light of MFN, or the TrumpRx channel that we launched. That said, MFN also gives us improved visibility into pricing down the road. So that's one of the positives in this deal. Pergoveris, by contrast, kept growing at a double-digit rate, 14% in Q2. That was a bit lower than in earlier quarters, largely because of comps. So there's nothing to be concerned about there, but it's still double digit. In fact, I'd say we remain extremely enthusiastic about what's ahead for Pergoveris, including the recent launch in China. And that's about it. Alongside that, there is a Saizen.
Danny Bar-Zohar
executiveHowever, as we mentioned, it rose in Q2, and against very difficult comparisons—that's the picture regarding Fertility.
Florian Schraeder
executiveThanks to all of you who joined today's discussion, and for your ongoing interest in Merck. That brings our Q2 '26 earnings call to a close.
Operator
operatorThank you, everyone, for joining us. That brings us to the end of this call. You’re welcome to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.